{"id":797441,"date":"2025-01-02T08:08:06","date_gmt":"2025-01-02T13:08:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/"},"modified":"2025-01-02T08:08:06","modified_gmt":"2025-01-02T13:08:06","slug":"pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/","title":{"rendered":"Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SOUTH SAN FRANCISCO, Calif., Jan.  02, 2025  (GLOBE NEWSWIRE) &#8212; Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, is scheduled to present at the 43<sup>rd<\/sup>\u00a0Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 1:30 p.m. Pacific Time at the Westin St. Francis Hotel in San Francisco.<\/p>\n<p>Interested parties may access the live webcast of this presentation by visiting the\u00a0Investors &amp; Media section of Pliant\u2019s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4lT87-mip0ia1s1U3Khwk0nqmQrvxoMAcD8nDs2NwMPWg2DeS70mqmnEzxxJP0YRj9ZSUaygYmitnEH8BGG4fw==\" rel=\"nofollow\" target=\"_blank\">www.PliantRx.com<\/a>. The replay of this webcast will be archived for 30 days following the conclusion of the event. <\/p>\n<p><strong>About Pliant Therapeutics, Inc.<\/strong><\/p>\n<p>Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant&#8217;s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of \u03b1<sub>v<\/sub>\u00df6 and \u03b1<sub>v<\/sub>\u00df<sub>1<\/sub> integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in IPF and PSC and Orphan Drug Designation from the European Medicines Agency in IPF and PSC. Pliant has initiated BEACON-IPF, an adaptive Phase 2b\/3 trial of bexotegrast in IPF. Pliant is conducting a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of \u03b1<sub>v<\/sub>\u00df<sub>8<\/sub> and \u03b1<sub>v<\/sub>\u00df<sub>1<\/sub> integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin \u03b1<sub>7<\/sub>\u03b2<sub>1<\/sub> targeting muscular dystrophies. <\/p>\n<p>For additional information, please visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4lT87-mip0ia1s1U3Khwk1UvUqTvCGKguNoUx7o_yJzQDJGB0uSqQcS-r-h8O6QGkfdx4HRnHuIc8z-mSFysSA==\" rel=\"nofollow\" target=\"_blank\"><u>www.PliantRx.com<\/u><\/a>. Follow us on\u00a0social media <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DYrSmsx_WZyEuzAmANRQ66DABHRLJncIPOl-8uhurY_KwEA7Cw69SNc2dgqbp-mk01uxeT9LS3jRRpGSBPMPoQ==\" rel=\"nofollow\" target=\"_blank\">X<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=V5hmXkxHbtsGNPmTIDdur18VBGnFrAPNDMZeTxsYPtTFjV6Z4kmX_QcRXmJldVIWwqwI-o7hJO41u-sdpoHTebi_SEDz85eIVDUkrgXVM5MIlsGMKEKPgCG0VnjONCJZ\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>, and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6Ak-3SOyRi0g8iNTx5fj6OJJDsBBPpvXFshzglBHBe7olwaaba-Ve2QnYcTkeDQ4BJ_ugT0lx9BfX7LAHeO1-6Fu1qfJNGz2yNC8JZxHh7U=\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a>.<\/p>\n<p>Investor and Media Contact:<\/p>\n<p>Christopher Keenan<br \/>Vice President, Investor Relations and Corporate Communications<br \/>Pliant Therapeutics, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wj5yk4-Zyh7rHGCV0fpLrLo90WG3MXBVSCycpGfLFhaJlhXQdBuGMZvMaQ8a4EVRZ8XZnfwaxn2R237jyvmFakIm8PQSSs9_S3uRM-6Tozcnu93PCZ_2tpWjmNwXKVr84-tX_DxgZGFxBiwdTpMKQ3xEBcMVsuDTkZJ9RFDlDcwVaUXrAo0EypZtL0mPbud1GBI_eDRfFgcoa_MifqlEQGnjeUxCX-bRyQrdWCEuU1s=\" rel=\"nofollow\" target=\"_blank\">ir@pliantrx.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNTU0OCM2Njc1ODI5IzIxODU0NzY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZTljOTYxOTQtYmNiNi00MTdlLThiZWMtMTY1NDNjZWNiNjlkLTExOTcwMzA=\/tiny\/Pliant-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) &#8212; Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, is scheduled to present at the 43rd\u00a0Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 1:30 p.m. Pacific Time at the Westin St. Francis Hotel in San Francisco. Interested parties may access the live webcast of this presentation by visiting the\u00a0Investors &amp; Media section of Pliant\u2019s website at\u00a0www.PliantRx.com. The replay of this webcast will be archived for 30 days following the conclusion of the event. About Pliant Therapeutics, Inc. Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-797441","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) &#8212; Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, is scheduled to present at the 43rd\u00a0Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 1:30 p.m. Pacific Time at the Westin St. Francis Hotel in San Francisco. Interested parties may access the live webcast of this presentation by visiting the\u00a0Investors &amp; Media section of Pliant\u2019s website at\u00a0www.PliantRx.com. The replay of this webcast will be archived for 30 days following the conclusion of the event. About Pliant Therapeutics, Inc. Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic &hellip; Continue reading &quot;Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-02T13:08:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNTU0OCM2Njc1ODI5IzIxODU0NzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference\",\"datePublished\":\"2025-01-02T13:08:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\\\/\"},\"wordCount\":320,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNTU0OCM2Njc1ODI5IzIxODU0NzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\\\/\",\"name\":\"Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNTU0OCM2Njc1ODI5IzIxODU0NzY=\",\"datePublished\":\"2025-01-02T13:08:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNTU0OCM2Njc1ODI5IzIxODU0NzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNTU0OCM2Njc1ODI5IzIxODU0NzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) &#8212; Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, is scheduled to present at the 43rd\u00a0Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 1:30 p.m. Pacific Time at the Westin St. Francis Hotel in San Francisco. Interested parties may access the live webcast of this presentation by visiting the\u00a0Investors &amp; Media section of Pliant\u2019s website at\u00a0www.PliantRx.com. The replay of this webcast will be archived for 30 days following the conclusion of the event. About Pliant Therapeutics, Inc. Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic &hellip; Continue reading \"Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-02T13:08:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNTU0OCM2Njc1ODI5IzIxODU0NzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference","datePublished":"2025-01-02T13:08:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/"},"wordCount":320,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNTU0OCM2Njc1ODI5IzIxODU0NzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/","name":"Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNTU0OCM2Njc1ODI5IzIxODU0NzY=","datePublished":"2025-01-02T13:08:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNTU0OCM2Njc1ODI5IzIxODU0NzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNTU0OCM2Njc1ODI5IzIxODU0NzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/797441","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=797441"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/797441\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=797441"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=797441"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=797441"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}